Pharmaxis extends scarring collaboration after encouraging results

–News Direct–

Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company has made great progress towards commercialisation in a Phase 1C study of its topical Pan LOX inhibitor, achieving a well-tolerated safety profile and a marked change in scar composition. Importantly, the study’s results mark the first-ever proof that LOX inhibition reduces skin collagen, having achieved a 30% reduction in the scar’s collagen content.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/pharmaxis-extends-scarring-collaboration-after-encouraging-results-117575065